# A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)

Source: https://onco.cc/trials/nct01827605/  
OnCo record `nct01827605` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ibritumomab tiuxetan in Follicular lymphoma, run by Fondazione Italiana Linfomi - ETS, completed.

## Summary

A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) is a phase 3 interventional study registered as NCT01827605 by Fondazione Italiana Linfomi - ETS, with 159 participants recorded, started 2012-01 and reaching its primary completion in 2019-10. Interventions recorded: ZEVALIN, BEAM. Conditions recorded: Relapsed Follicular Lymphoma.

Linked to the drug Ibritumomab tiuxetan because the registry names it among its interventions and Follicular lymphoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01827605
- Phase: 3
- Setting: A Phase III Multicenter,Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy Vs Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed/Refractory Follicular Lymphoma (FL) Aged 18-65 Years
- Sponsor: Fondazione Italiana Linfomi - ETS
- Enrolled: 159

## Sources

- ClinicalTrials.gov NCT01827605: https://clinicaltrials.gov/study/NCT01827605

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- drugs: [Ibritumomab tiuxetan](https://onco.cc/drugs/ibritumomab-tiuxetan/)

---
JSON: https://onco.cc/api/v1/entities/nct01827605.json